Quest Diagnostics (DGX), a renowned diagnostic testing services company, is fully equipped for the future of healthcare. Ahead of the upcoming
Q3 results, analysts are expressing optimism related to DGX's valuation. The company remains focused on enhancing efficiency to improve its long-term profit outlook. There's anticipation for
earnings growth to be reported during next week's disclosure. DGX has received a price target upgrade from Mizuho, revealing a potential 3.05% upside in the healthcare sector. Initiatives such as its Industry-First Epic Collaboration aims to overhaul the laboratory testing experience. Moreover, Quest's Shield Partnership is under survey for its potential transformative impact on preventive health innovation. DGX's performance has shown compelling growth in dividends and several partnerships to expand its services - from Fresenius Medical Care, Corewell Health, and Guardant Health. Additionally, Quest's expansion of services with a
Google Cloud collaboration reveals a dynamic approach to adopt generative AI for personalized customer experiences. However, concerns still linger, such as the impacts of tariff and Medicare Act risks.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Fri, 17 Oct 2025 14:31:32 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 4
